Category: Arthritis

Description

This page contains brief details about the drug adalimumab, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.

Date of Approval

Adalimumab is a monoclonal antibody (protein which attaches to a specific target) which was approved for its medical use on 31st December 2002.

Mechanism of Action of Adalimumab

Adalimumab Injection is a biological agent that acts as targeted drug therapy to treat various inflammatory conditions. Adalimumab specifically targets and binds to the tnf Alpha. tnf Alpha a protein that is present in high concentrations in inflammatory diseases. adalimumab blocks the interaction of this protein with its receptors and eventually lower the inflammation.

Uses of Adalimumab

Adalimumab Injection has been developed to treat various inflammatory conditions like rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, enthesitis-related arthritis, ankylosing spondylitis, axial spondylarthritis without evidence of ankylosing spondylitis, psoriatic arthritis, plaque psoriasis, hidradenitis suppurativa, Crohn’s disease, ulcerative colitis and non-infective uveitis.

Adalimumab Dosage available

For adults with rheumatoid arthritis, psoriatic arthritis and ankylosing Spondylitis, the recommended dose is 40mg every other week. for children with Arthritis of unknown origin, the recommended dose is 10mg every other week for body weight less than 15 kg, 20mg every other week for body weight less than 30kg and 40mg every other week for body weight above 30kg.

For adults with inflammatory bowel disease like crohn’s disease and ulcerative colitis, the recommended dose is 160 MG on day 1, 80mg on 15th day and 40mg every other week starting on day 29. for children body weight less than 40 kg, the recommended dose is 80mg on first day, 40mg on day 15 and 20mg every other week starting on 29th day.

In case of plaque psoriasis and adult uveitis, initial dose is 80 mg followed by 40 mg every other week after initial dose. adalimumab is available as single dose prefilled pen (80mg/0.8ml, 40mg/0.8ml, 40mg/0.4ml) single dose prefilled glass syringe (80mg/0.8ml, 40mg/0.8ml, 40mg/0.4ml, 20mg/0.4ml, 20mg/0.2ml, 10mg/0.2ml, 10mg/0.1ml) and single dose glass vial (40mg/0.8ml).

Description

This page contains brief details about the drug itolizumab, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.

Date of Approval

Itolizumab is an immunomodulatory monoclonal antibody (protein which attaches to a specific target) which was approved for its medical use on January 2013.

Mechanism of Action of Itolizumab

Itolizumab Injection is a biological agent that belongs to the category of medications called monoclonal antibodies. Itolizumab specifically targets and binds to the domain 1 of the human CD6 cells, resulting in significant decrease in the inflammatory mediators. Itolizumab inhibits the availability of T cells without depleting them and eventually lowers the inflammation.

Uses of Itolizumab

Itolizumab Injection has been developed to treat moderate to severe plaque psoriasis, psoriatic arthritis and rheumatoid arthritis. It is also increasingly used to reduce inflammation and cytokine release in COVID-19 patients.

Itolizumab Dosage available

In case of plaque psoriasis and cytokine release syndrome, initial dose is 1.6mg/kg indicated as an intravenous infusion. For plaque psoriasis, a dose of 1.6mg/kg in administered every 2 weeks for 12 weeks, followed by 1.6mg/kg every 4 weeks up to 24 weeks. Approximately 50ml will be administered in the first hour, followed by the remaining dose within the next hour. For patients with cytokine release syndrome, the first infusion of 1.6mg/kg will be initiated at the rate of 25ml/hr in the first hour, followed by 50ml/hr for the next 5-6 hours if well tolerated. Itolizumab is available as single dose vial of injection, intended for IV infusion with each vial containing 100mg Itolizumab (rDNA origin).

Description

This page contains brief details about the drug tocilizumab, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.

Date of Approval

The U.S. FDA approved tocilizumab on 08/01/2010. This medicine belongs to a group of monoclonal antibodies (a protein made from specific immune cells).

Mechanism of Action of Tocilizumab

The medication inhibits the function of a particular protein known as interleukin-6, which plays a role in the body’s inflammatory responses. By blocking this protein, it can help decrease inflammation within your body.

Uses of Tocilizumab

This is used in conditions such as moderate to severe active rheumatoid arthritis (RA) and who have inadequate response with other rheumatoid drugs, giant cell arteritis (disease in arteries), children with systemic juvenile idiopathic arthritis (sJIA), polyarticular juvenile idiopathic arthritis (pJIA).

Tocilizumab Dosage available

The medicine will be administered to you by a healthcare professional in a hospital setting. It is usually administered in the vein (intravenous). Your doctor will decide the dose, route of administration, and frequency based on your disease condition and other factors.